文献速递血栓与止血

急性呼吸窘迫综合征的纤溶异常与溶栓药物治疗COVID-19的多样性

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
PubMed 文献 · J Thromb Haemost · 2020-06-03

本文综述了COVID-19相关ARDS中纤溶异常的机制,包括肺内纤维蛋白沉积、D-二聚体和纤维蛋白原升高、PAI-1升高导致低纤溶状态。文章讨论了抗凝预防的重要性,并提出雾化纤溶药物(如tPA)靶向降解肺内纤维蛋白、改善氧合的治疗潜力。

要点

  • COVID-19患者常见D-二聚体和纤维蛋白原升高,肺内纤维蛋白沉积。
  • PAI-1升高导致低纤溶状态,促进纤维蛋白沉积。
  • 雾化tPA可能靶向降解肺内纤维蛋白,改善氧合。

核心结论

  • COVID-19相关ARDS存在低纤溶状态,雾化纤溶药物可能靶向降解肺内纤维蛋白并改善氧合。

研究设计与样本

  • 本文为综述,讨论COVID-19相关ARDS的纤溶异常及溶栓药物再利用。

主要发现

  • ARDS一致发现肺泡和肺实质纤维蛋白沉积。
  • COVID-19患者D-二聚体和纤维蛋白原升高。
  • 损伤肺泡内皮细胞和白细胞表面组织因子暴露促进纤维蛋白沉积。
  • 肺上皮和内皮细胞来源的PAI-1显著升高造成低纤溶状态。

临床怎么用

  • COVID-19患者使用低分子肝素预防治疗对限制凝血病重要。
  • 为降解肺内已存在的纤维蛋白,需促进局部纤溶。
  • 雾化纤溶酶原激活剂可能靶向降解纤维蛋白并改善危重患者氧合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Whyte CS, Morrow GB, Mitchell JL, et al. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020. PMID: 32329246. doi:10.1111/jth.14872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。